屈光手术后眼部症状轨迹:LASIK与PRK的前瞻性多中心队列研究
该前瞻性多中心队列研究纳入326例接受双侧LASIK或PRK的成人,术前及术后第1天、第3个月、第6个月评估眼部疼痛强度。结果显示疼痛轨迹异质:28.8%无临床相关疼痛,43.9%仅术后第1天疼痛,18.1%疼痛持续至术后3或6个月; prolonged pain独立关联PRK、术前润滑滴眼液使用、慢性下腰痛及较高眼表症状负担。
要点
- 屈光术后疼痛轨迹异质,18.1%患者疼痛持续至术后3或6个月。
- PRK较LASIK与疼痛持续风险独立相关(OR 2.73)。
- 术前润滑滴眼液使用、慢性下腰痛及较高干眼问卷评分与疼痛持续相关。
核心结论
- 屈光术后眼部症状轨迹呈不同纵向模式,且与特定基线因素相关。
- 基于轨迹的症状特异性方法可能有助于风险分层、咨询和围手术期管理,但需进一步验证。
研究设计与样本
- 前瞻性多中心队列研究,在美国2个学术眼科中心开展,2021年4月至2025年7月。
- 纳入接受双侧LASIK或PRK的成人,排除妊娠、角膜异常、可能混淆眼痛的疾病及年龄小于18岁者。
- 共326例参与者具有完整疼痛数据,平均年龄34.3岁(SD 7.9),女性196例(60.1%)。
- 术前及术后第1天、第3个月、第6个月评估眼部疼痛强度(NRS 0-10),临床相关疼痛定义为NRS≥3。
主要发现
- 94例(28.8%)无临床相关疼痛,143例(43.9%)仅术后第1天疼痛,59例(18.1%)疼痛持续至术后3或6个月,30例为不常见轨迹。
- 疼痛持续独立关联PRK(较LASIK:OR 2.73;95%CI 1.29-5.77)。
- 疼痛持续独立关联术前润滑滴眼液使用(OR 2.41;95%CI 1.17-4.96)。
- 疼痛持续独立关联慢性下腰痛(OR 2.45;95%CI 1.14-5.25)。
- 疼痛持续独立关联较高5项干眼问卷评分(OR 1.11;95%CI 1.01-1.22);术后6个月角膜染色与疼痛持续风险降低相关(OR 0.79;95%CI 0.64-0.97)。
关键数值与推荐
- 临床相关疼痛定义为NRS评分≥3。
- 疼痛轨迹基于各时间点临床相关疼痛的有无进行分类。
临床怎么用
- 可利用术前润滑滴眼液使用、慢性下腰痛及干眼问卷评分识别疼痛持续高风险患者。
- 对PRK患者应加强围手术期疼痛管理预期和咨询。
- 术后第1天及第3、6个月随访时系统评估眼部疼痛,有助于识别 prolonged pain。
局限性
- 研究结论需进一步证实。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Characterizing individual ocular symptom trajectories following laser-assisted in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) may provide a longitudinal, patient-centered perspective on postoperative recovery and help identify patients at risk of prolonged symptom courses. OBJECTIVE: To characterize longitudinal ocular symptom trajectories after refractive surgery, describe associated symptom descriptors over time, and identify baseline factors associated with pain trajectories. DESIGN, SETTING, AND PARTICIPANTS: This prospective, multicenter cohort study was conducted at 2 academic ophthalmology centers in the US from April 2021 to July 2025. Adults undergoing bilateral LASIK or PRK were enrolled and evaluated preoperatively and at postoperative day 1 (POD 1) and months 3 (POM 3) and 6 (POM 6). Participants eligible for refractive surgery were included. Exclusion criteria included pregnancy, corneal abnormality (scar, ectasia, corneal surgery), eye diseases that could confound ocular pain (glaucoma, herpetic eye disease), and age younger than 18 years. MAIN OUTCOMES AND MEASURES: Ocular pain intensity measured using numerical rating scale (NRS; 0-10) at baseline, POD 1, POM 3, and POM 6. Clinically relevant pain was defined as an NRS score of 3 or greater. Trajectories were classified based on clinically relevant pain presence across time points; baseline demographic, clinical, surgical, and ocular surface factors were evaluated as associated factors. RESULTS: Among 326 participants with complete pain data (mean [SD] age, 34.3 [7.9] years; 196 [60.1%] female), pain trajectories were heterogeneous. No clinically relevant pain was observed in 94 participants (28.8%), pain at POD 1 only in 143 participants (43.9%), and prolonged pain (at POM 3 or POM 6) in 59 participants (18.1%); 30 participants had uncommon pain trajectories. Prolonged pain was independently associated with PRK (vs LASIK: odds ratio [OR], 2.73; 95% CI, 1.29-5.77) and several preoperative factors, including lubricating drop use (OR, 2.41; 95% CI, 1.17-4.96), chronic low back pain (OR, 2.45; 95% CI, 1.14-5.25), and greater ocular symptom burden (5-Item Dry Eye Questionnaire score: OR, 1.11; 95% CI, 1.01-1.22). The presence of corneal staining at 6 months after surgery was associated with lower odds of prolonged pain (OR, 0.79; 95% CI, 0.64-0.97). CONCLUSIONS AND RELEVANCE: In this cohort study, postoperative ocular symptom trajectories after refractive surgery followed distinct longitudinal patterns, suggesting these trajectories may have been associated with specific baseline factors. This trajectory-based, symptom-specific approach may provide clinically relevant insight into patient recovery and may improve risk stratification, counseling, and targeted perioperative management, but further corroboration is warranted.
引用
- Kang S, Betz JD, Locatelli EVT, et al. Ocular Symptoms After Refractive Surgery. JAMA Ophthalmol. 2026. PMID: 42424051. doi:10.1001/jamaophthalmol.2026.2500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。